Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01470144 | Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension | PHASE3 | COMPLETED | 41 | — | — | Jun 1, 2011 | Jul 1, 2015 | Feb 4, 2025 | - | — |
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Single arm, open-label |
| Name | Type | Description |
|---|---|---|
| Epoprostenol | DRUG | Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit |
Inclusion Criteria: 1. Signed informed consent prior to initiation of any study-mandated procedure 2. Patients who completed participation in study AC-066A301 3. Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301 Exclusion Criteria: 1....